

After JPM, What Are the Legal Dealmaking Trends to Watch?

WRITTEN BY

Thomas M. Rose | Heather Morehouse Ettinger, Ph.D.

The 41st Annual J. P. Morgan Healthcare Conference came and went this year in its usual flurry of activity, as health care and life sciences industry leaders converged on San Francisco to present on the most pressing issues and trends facing investors in the year to come. It was also the first time the annual conference was conducted in-person since the COVID-19 pandemic began.

The health care and life sciences industries experienced a difficult 2022, due to halted IPOs and plummeting valuations. Many companies found themselves at the end of their cash runways and were left with the difficult choice of either cutting back operations or seeking financing at a lower valuation to keep the lights on.

However, 2023 has a brighter outlook. Big Pharma is now on the hunt for innovation to replenish IP portfolios, and investors are seeing the promise of M&A and other strategic collaborations on the horizon.

After another insightful conference this year, these are some of the key legal deal trends to expect from the health care and life sciences industries in 2023.

[Click here to read the full article on *MedCity News*.](#)

RELATED INDUSTRIES + PRACTICES

- [Life Sciences Transactions](#)